Welcome to our dedicated page for Alpha Teknova SEC filings (Ticker: TKNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Alpha Teknova’s intricate disclosures—ranging from reagent margin swings to modular plant capacity—can feel overwhelming. Each 10-K, 10-Q, or sudden 8-K is dense with technical language on buffers, cell-culture media, and RUO+ production grades. If you have ever searched “Alpha Teknova SEC filings explained simply” or wondered where to find the “Alpha Teknova annual report 10-K simplified,” you already know the challenge.
Stock Titan removes that barrier. Our AI reviews every Alpha Teknova quarterly earnings report 10-Q filing, highlights revenue shifts tied to Build-Tek demand, and presents concise summaries you can read in minutes. The moment an “Alpha Teknova Form 4 insider transactions real-time” notice hits EDGAR, we alert you to “Alpha Teknova executive stock transactions Form 4,” so you never miss critical moves. Need governance details? Dive into the “Alpha Teknova proxy statement executive compensation” section, with pay data automatically linked to production milestones. Our platform also offers side-by-side comparisons that make “understanding Alpha Teknova SEC documents with AI” straightforward.
Whether you’re monitoring “Alpha Teknova insider trading Form 4 transactions” ahead of a facility expansion or scanning an “Alpha Teknova 8-K material events explained” update on supply agreements, every filing is indexed seconds after release. Use our dashboards for “Alpha Teknova earnings report filing analysis,” export tables directly to your models, and rely on real-time updates across all forms. Complex biotech filings become clear, letting you focus on informed decisions—not document hunting.
Alpha Teknova (TKNO) reported Q3 2025 results. Revenue was $10.5 million, up 9.2% year over year. Gross margin improved to 30.7% from 0.9% a year ago, reflecting the absence of prior-year inventory charges. Operating loss narrowed to $4.0 million, and net loss was $4.3 million (net loss per share of $0.08).
For the first nine months, revenue reached $30.5 million (up 7.2%) with a 33.4% gross margin. General and administrative costs fell year over year, contributing to a smaller operating loss. Cash and cash equivalents plus short‑term investments totaled $22.1 million as of September 30, 2025, within $29.6 million of net working capital.
The company’s amended credit facility totals $28.245 million (term loan and revolver) and includes covenants, including a minimum trailing‑twelve‑month net revenue of $39.0 million for the period ending December 31, 2025, and a minimum cash requirement of $8.0 million. Shares outstanding were 53,529,174 as of November 5, 2025.
Alpha Teknova (TKNO) furnished Q3 results. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The release was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01, with the full text included as Exhibit 99.1.
The materials are designated as furnished, not filed, under the Exchange Act.
Alpha Teknova, Inc. reported revenue of $10.3 million for the quarter ended June 30, 2025, up 7.0% from the prior-year quarter, and $20.1 million for the six months ended June 30, 2025, up 6.2% year-over-year. Gross profit improved materially, with gross margin rising to 38.7% for the quarter (from 29.2%) and to 34.8% for the six months (from 26.5%), driven by stated manufacturing efficiency gains and higher revenue.
The company recorded a net loss of $3.6 million in the quarter and $8.2 million for the six-month period; net loss per share was $0.07 and $0.15, respectively. Balance sheet highlights include total assets of $110.5 million, cash of $3.3 million and short-term held-to-maturity investments of $20.7 million (combined $24.0 million), long-term debt, net of $13.0 million, and stockholders' equity of $76.1 million. The company reports $31.6 million in net working capital.
Liquidity is supported by a $28.245 million credit facility (a $23.245 million term loan and a $5.0 million revolver) that matures in 2030; the facility includes a $39.0 million trailing 12-month minimum net revenue covenant and an $8.0 million minimum cash covenant. Notable concentrations disclosed include Distributor customer A representing 22% of revenue for the quarter and a distributor supplier representing 26% of inventory purchases. The filing shows progress on margin improvement and cost control but the company remains unprofitable with existing debt and concentration risks.
Alpha Teknova, Inc. (TKNO) – Form 4 insider filing dated 06/25/2025
The filing reports one transaction by Alexander Vos, a non-employee Director of Alpha Teknova. On 17 June 2025 Mr. Vos received 54,300 restricted stock units (RSUs) of common stock, coded “A” (award of securities). The RSUs were granted at a stated price of $0.00; they will vest in full on the first anniversary of the grant date (17 June 2026).
Following the award, Mr. Vos’ total reported beneficial ownership increased to 102,472 common shares, held directly. No derivative securities were involved and no shares were sold.
Implications for investors
- The filing reflects equity-based compensation rather than an open-market purchase or sale, so cash did not change hands.
- The incremental dilution from 54,300 shares is immaterial relative to Alpha Teknova’s outstanding share count (outstanding figure not provided in the filing).
- The award lengthens the director’s equity exposure, which can better align board incentives with shareholder interests over the next 12 months.
FAQ
What is the current stock price of Alpha Teknova (TKNO)?
What is the market cap of Alpha Teknova (TKNO)?
